Trial Information

Summary: Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.

Patient Inclusion Criteria

• Genders Eligible for Study: Both
• Diagnosis of Schizophrenia
• 18-65 years
• No hospitalization for an exacerbation of schizophrenia within two months prior to screening and during the screening period

Patient Exclusion Criteria

• Subjects who are acutely psychotic or subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
• At significant risk of suicide, and the potential for violent behavior (likely to harm themselves or others) based on history

For more information,

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:30:28 AM